Biodexa Pharmaceuticals Plc (BDRX) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access BDRX Annual Income Statement →
Quarterly income statement trends provide context on Biodexa Pharmaceuticals Plc's margins, operating leverage, and earnings trajectory.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Research and Development Expense-3.96
Other Operating Expense / -Income12.61
Total operating costs including COS8.65
Operating income / -loss-8.65
Net Interest (-)Expense / Income0.00
Other loss / -income-2.16
Total costs & expenses6.49
Income & Taxes
Income / -loss before income taxes-6.49
Income taxes expenses / -benefit-0.11
Income after income taxes-6.38
Net income / -loss of other equity0.00
Income / -loss from continuing operations-6.38
Net income / -loss-6.38
Income / -loss to shareholder-6.38
EBIT-6.49
EBITD-6.44
EBITDA-6.44
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Diluted Net EPS0.00
4 historic quarters locked

Sign in to unlock the full Biodexa Pharmaceuticals Plc income statement history.

About BDRX Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.